Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Supernus Pharmaceuticals Announced FDA Approval of product ONAPGO for the Treatment of Motor Fluctuations in Adults with Advanced Parkinson’s Disease

February 5, 2025 0

Supernus Pharmaceuticals Supernus Pharmaceuticals (SUPN) - a biopharmaceutical company focused on developing products for the treatment …

CHMP Issued Positive Opinion for Subcutaneous RYBREVANT® Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

February 3, 2025 0

Halozyme Therapeutics Halozyme Therapeutics (HALO) announced that Janssen-Cilag International NV, a Johnson & Johnson company, received …

Vertex Outstanding and Promising News

January 31, 2025 0

Vertex Pharmaceuticals Yesterday, January 30, 2025, Vertex Pharmaceuticals (VRTX) announced FDA approval of journavx™(suzetrigine), a First-in-Class …

The U.S. FDA Approved Daiichi Sankyo and AstraZeneca’s Product ENHERTU® for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following Disease Progression After One or More Endocrine Therapies

January 29, 2025 0

AstraZeneca FDA Approval On January 27, 2025, Daiichi Sankyo (TSE: 4568) and AstraZeneca (AZN) product ENHERTU® (fam-trastuzumab …

Complete Preliminary Week 96 Results from Akero Therapeutics EFX Results

January 27, 2025 0

Akero Therapeutics Full Press Release Following our shortened report earlier today, this posting is from the …

Akero Therapeutics Successful Results

January 27, 2025 0

Akero Therapeutics Waiting to hear the news from Akero Therapeutics in treating NASH, the company reported …

Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor

January 13, 2025 0

Vera Therapeutics in the Market Today Today, many investors in the biotechnology market caused a selloff …

Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors.

January 8, 2025 0

Compugen January 8, 2025, Compugen (CGEN), announced that the first patient was dosed in a Phase …

Halozyme Therapeutics Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance

January 8, 2025 0

Halozyme Therapeutics Today, January 8, 2025 /PRNewswire/ - Halozyme Therapeutics, Inc. (HALO) provided a financial update, …

Prescribing Specialists Confirm Success of Verona Pharma Product Ohtuvayre in Maintaining COPD Treatment

January 7, 2025 0

Verona Pharma Today, January 7, 2024 Verona Pharma (VRNA) announced preliminary unaudited net product sales for …

A Reminder: Verastem Oncology Announced FDA Acceptance and Priority Review of the NDA Avutometinib (in Combination with Defactinib) for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

January 6, 2025 0

Verastem Oncology in the NEWS On December 30, 2024, Verastem Oncology (VSTM) announced that the U.S. …

Vertex Announces US FDA Approval of ALYFTREK™ Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis

December 23, 2024 0

Vertex Pharmaceuticals Vertex Pharmaceuticals (VRTX) announced a United States FDA has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily …

Revisiting Bluebird Bio Inc

December 18, 2024 0

Bluebird Bio Inc For investors who thought that bluebird bio Inc (BLUE) stock price jumped up …

Broadcom Inc’s Greatest Day

December 13, 2024 0

Broadcom Inc Q4 Financial Results for Broadcom Inc (AVGO) reported financial results for its fourth quarter …

Novo Nordisk: European Regulatory Authority Adopts Positive Opinion for an Update of Ozempic® Label to Reflect Risk Reduction of Kidney Disease-Related Events

December 12, 2024 0

Novo Nordisk Bagsværd, Denmark, 12 December 2024 – Novo Nordisk (NVO) announced that the European Medicines …

Johnson & Johnson Product CARVYKTI® Improves Standard of Care Therapies for Relapsed or Refractory Multiple Myeloma

December 11, 2024 0

Johnson & Johnson On December 9, 2024, Johnson & Johnson (JNJ) announced new results from the Phase …

At ASH 2024, Gilead Sciences’ Kite’s Yescarta® Shows Its CAR T-Cell Therapy Uniquely Durable Response and Long-Term Survival After Five Years in Patients with Relapsed/Refractory Non-Hodgkin Lymphomas

December 10, 2024 0

Gilead Sciences Kite Pharma, a Gilead Sciences Company (GILD) announced results from a five-year follow-up analysis …

From ASH: Vertex Pharmaceuticals Presented Positive Durability Gene Editing CASGEVY for Severe Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia

December 9, 2024 0

Vertex Pharmaceuticals ASH Announcement Today, December 8, 2024, Vertex Pharmaceuticals (VRTX) announced longer-term data for CASGEVY™ …

Intra-Cellular Therapies Submits Supplemental New Drug Application to the US FDA for CAPLYTA® Treatment of Major Depressive Disorder as Adjunctive Therapy

December 6, 2024 0

Intra-Cellular Therapies in the NEWS On December 3, 2024, Intra-Cellular Therapies (ITCI) announced the submission of …

Nuvig Therapeutics Announces $161 Million Series B Financing, Plus Its Progression to Phase 2 with Novel, Second-Generation Immunomodulator

December 5, 2024 0

Nuvig Therapeutics in the NEWS Nuvig Therapeutics – a privately held biotech company, developing novel immunomodulatory therapeutics …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Supernus Pharmaceuticals Announced FDA Approval of product ONAPGO for the Treatment of Motor Fluctuations in Adults with Advanced Parkinson’s Disease

CHMP Issued Positive Opinion for Subcutaneous RYBREVANT® Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Vertex Outstanding and Promising News

The U.S. FDA Approved Daiichi Sankyo and AstraZeneca’s Product ENHERTU® for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following Disease Progression After One or More Endocrine Therapies

Complete Preliminary Week 96 Results from Akero Therapeutics EFX Results

Akero Therapeutics Successful Results

Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor

Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors.

Halozyme Therapeutics Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance

Prescribing Specialists Confirm Success of Verona Pharma Product Ohtuvayre in Maintaining COPD Treatment

A Reminder: Verastem Oncology Announced FDA Acceptance and Priority Review of the NDA Avutometinib (in Combination with Defactinib) for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Vertex Announces US FDA Approval of ALYFTREK™ Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis

Revisiting Bluebird Bio Inc

Broadcom Inc’s Greatest Day

Novo Nordisk: European Regulatory Authority Adopts Positive Opinion for an Update of Ozempic® Label to Reflect Risk Reduction of Kidney Disease-Related Events

Johnson & Johnson Product CARVYKTI® Improves Standard of Care Therapies for Relapsed or Refractory Multiple Myeloma

At ASH 2024, Gilead Sciences’ Kite’s Yescarta® Shows Its CAR T-Cell Therapy Uniquely Durable Response and Long-Term Survival After Five Years in Patients with Relapsed/Refractory Non-Hodgkin Lymphomas

From ASH: Vertex Pharmaceuticals Presented Positive Durability Gene Editing CASGEVY for Severe Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia

Intra-Cellular Therapies Submits Supplemental New Drug Application to the US FDA for CAPLYTA® Treatment of Major Depressive Disorder as Adjunctive Therapy

Nuvig Therapeutics Announces $161 Million Series B Financing, Plus Its Progression to Phase 2 with Novel, Second-Generation Immunomodulator